← Back to patent-cliff list
Cariprazine hydrochloride (Chengdu Kanghong Pharmaceutical)
Tier C — Watch / tradeCariprazine hydrochloride (Chengdu Kanghong Pharmaceutical)
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：5-HT2A, DRD2, DRD3, HRH1, 5-HT2B, 5-HT1A
Indications (approved)：Schizophrenia
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Cariprazine hydrochloride (Chengdu Kanghong Pharmaceutical)?
Approved indications include: Schizophrenia.
When does the Cariprazine hydrochloride (Chengdu Kanghong Pharmaceutical) patent expire?
No public expiry year is available for Cariprazine hydrochloride (Chengdu Kanghong Pharmaceutical) yet; this page updates once verified.
How do I get a quote for Cariprazine hydrochloride (Chengdu Kanghong Pharmaceutical) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01